Pro zobrazení tohoto obsahu je třeba být přihlášen.
Author Archives for m.popovic@wemakemedia.cz
OBINUTUZUMAB PLUS DHAP FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION PLUS OBINUTUZUMAB MAINTENANCE PROVIDES A HIGH MRD RESPONSE RATE IN UNTREATED MCL PATIENTS, LYMA-101 TRIAL – A LYSA TRIAL
15 septembra, 2020 7:11 pm Leave your thoughtsAuthor(s): S Legouill, Asma Beldi-Ferchiou, Victoria Cacheux, et. al. EHA Library. Le Gouill S. Jun 14, 2019; 267304; S103 ...
BLINATUMOMAB FOR MINIMAL RESIDUAL DISEASE (MRD) IN ADULTS WITH BCELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BCPALL): MEDIAN OVERALL SURVIVAL (OS) NOT REACHED AT 5 YEARS FOR COMPLETE MRD RESPONDERS
15 septembra, 2020 7:11 pm Leave your thoughtsAuthor(s): Nicola Goekbuget, Hervé Dombret, Gerhard Zugmaier, et. al. EHA Library. Goekbuget N. Jun 16, 2019; 267373; S1619 Abstract:...
Cílená terapie a léčebné režimy u chronické lymfocytární leukemie a maligních lymfomů
15 septembra, 2020 7:11 pm Leave your thoughtsLetošní 24. kongres Evropské hematologické společnosti se v oblasti léčby chronické lymfocytární leukemie zaměřil na cílenou terapii a v řadě sdělení na léčebné...
A RANDOMIZED, DOUBLE BLIND PHASE 2 STUDY OF 3 DIFFERENT DOSES OF PRM-151 IN PATIENTS WITH MYELOFIBROSIS WHO WERE PREVIOUSLY TREATED WITH OR INELIGIBLE FOR RUXOLITINIB
15 septembra, 2020 7:11 pm Leave your thoughtsAuthor(s): Srdan Verstovsek, Moshe Talpaz, Martha Wadleigh, et. al. EHA Library. Verstovsek S. Jun 15, 2019; 267411; S828 Abstract:...
RESULTS FROM ONGOING PHASE 1/2 CLINICAL TRIAL OF TAGRAXOFUSP (SL-401) IN PATIENTS WITH INTERMEDIATE, OR HIGH RISK, RELAPSED/REFRACTORY MYELOFIBROSIS
15 septembra, 2020 7:11 pm Leave your thoughtsAuthor(s): Naveen Pemmaraju, Haris Ali, Vikas Gupta EHA Library. Pemmaraju N. Jun 14, 2019; 266467; PF668 Abstract: PF668 ...
MOLECULAR ANALYSIS IN MAJIC PV CORRELATION WITH CLINICAL ENDPOINTS
15 septembra, 2020 7:11 pm Leave your thoughtsAuthor(s): Natalia Curto-Garcia, Joanna Baxter, Erica Harris, et. al. EHA Library. Curto-Garcia N. Jun 16, 2019; 267361; S1607 Abstract:...
HOW TO PREDICT RESPONSE TO RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS
15 septembra, 2020 7:11 pm Leave your thoughtsAuthor(s): María Isabel Montero, Marta Reinoso, Laura Pérez-Ortega, et. al. EHA Library. Reinoso M. May 16, 2019; 268124; PB2215 ...
SAFETY AND EFFICACY OF RUXOLITINIB (RUX) IN PATIENTS WITH MYELOFIBROSIS (MF) AND ANEMIA (HB <10 G/DL): RESULTS AT WEEK (WK) 24 OF THE REALISE TRIAL
15 septembra, 2020 7:11 pm Leave your thoughtsAuthor(s): Francisco Cervantes, Heinz Gisslinger, Atanas Radinoff, et. al. EHA Library. Cervantes F. Jun 15, 2019; 267082; PS1465 Abstract:...
Novinky z kongresu: Myeloproliferatívna neoplázia
15 septembra, 2020 7:11 pm Leave your thoughtsPo šiestich rokoch sa kongres európskej hematologickej asociácie vrátil do hlavného mesta Holandska. Program kongresu zahŕňal všetky podkategórie hematológie a choroby...
RANDOMIZED, OPEN-LABEL, NON-INFERIORITY, PHASE III STUDY OF SUBCUTANEOUS (SC) VERSUS INTRAVENOUS (IV) DARATUMUMAB (DARA) ADMINISTRATION IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: COLUMBA
15 septembra, 2020 7:10 pm Leave your thoughtsAuthor(s): Maria-Victoria Mateos, Hareth Nahi, Wojciech Legiec, et. al. EHA Library. Mateos M. Jun 15, 2019; 267406; S823 Abstract:...